NeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain Relief

NeuroMetrix (Nasdaq:NURO), reported publication of results from a clinical study of Quell® in the Journal of Pain Research.  The paper is titled “Effectiveness of fixed-site high-frequency transcutaneous electrical nerve stimulation in chronic pain: a large-scale, observational study.”  It is available for download at: Journal of Pain Research.

As quoted in the press release:

The design was a retrospective, observational cohort study that examined changes in chronic pain outcomes following 60 days of Quell use. The study data were obtained from Quell users who consented to upload their device usage and clinical data to the Quell Health Cloud and who rated their pain at baseline (before starting Quell therapy) and 60 days later.  The primary outcome measures were changes in pain intensity and pain interference with sleep, activity, and mood on an 11-point numerical rating scale. Dose–response associations were evaluated by stratifying subjects into low (≤30 days), intermediate (31–56 days), and high (≥57 days) utilization.

The study population consisted of 713 subjects.  The average age was 55 years and 52% were female. Most subjects had chronic pain for over 3 years.  The subjects had 5 sites of pain on average and complex medical histories with arthritis (62%), prior low back injury (41%), herniated disc (30%), spinal stenosis (29%) and fibromyalgia (26%) as the most common. At baseline, 47% of the subjects had severe pain.

Click here to read the full press release.